Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 26Neoplasms 7Liver Neoplasms 7Leukemia, Myeloid, Acute 6Carcinoma, Renal Cell 5Breast Neoplasms 5Recurrence 3Leukemia 3Kidney Neoplasms 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Melanoma 2Leukemia, Myelomonocytic, Chronic 2Gliosarcoma 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1

Interventions

carotuximab 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenoma, Liver Cell × Sorafenib × Clear all
NCT01306058 2019-01-23

Sorafenib and TRC105 in Hepatocellular Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 32 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Liver Neoplasms, Experimental, Adenoma, Liver Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡